



UNITED STATES
NUCLEAR REGULATORY COMMISSION
REGION I
2100 RENAISSANCE BLVD.
KING OF PRUSSIA, PA 19406-2713

June 14, 2017

James G. Baxter, Ph.D.
Senior Vice President, Development
Boehringer Ingelheim Pharmaceuticals, Inc.
900 Ridgebury Road
P.O. Box 368
Ridgefield, CT 06877-0368

SUBJECT: BOEHRINGER INGELHEIM PHARMACEUTICALS, INC., REVIEW OF
FINANCIAL ASSURANCE, MAIL CONTROL NO. 599809

Dear Dr. Baxter:

We have reviewed the Decommissioning Funding Plan Update revised April 24, 2017, and the letter dated May 19, 2017, to meet the financial assurance requirements for your license. We have no further questions at this time.

The following documents currently provide your financial assurance:

Decommissioning Funding Plan, revised April 24, 2017 [ML17125A224], and letter dated May 19, 2017 [ML17156A635];
Certification of Financial Assurance, dated October 5, 2007 [ML072890300];
Letter of Credit dated January 15, 2007 [ML070040206]; Amendment 1 dated October 2, 2007 [ML072890300]; Notification Letter, dated January 1, 2009, of contact information and Letter of Credit number change [ML090350449];
Standby Trust Agreement, received March 23, 2007 [ML070860428]; Amendment 1, dated October 18, 2007 [ML073040098]; and Amendment 2 dated May 16, 2011 [ML111670789]

Your organization uses a Decommissioning Funding Plan (DFP) to determine the amount of financial assurance necessary to fund all decommissioning activities. 10 CFR 30.35(e)(2) requires that, at the time of license renewal and at intervals not to exceed three years, the DFP must be resubmitted with adjustments as necessary to account for changes in costs and the extent of contamination. Your currently approved DFP was submitted on April 28, 2017; therefore, your DFP must be re-submitted on or before April 28, 2020. The DFP must update the information submitted with the original or prior approved DFP, and must specifically consider the effect of the following events on decommissioning costs: (1) spills of radioactive material producing additional residual radioactivity in onsite subsurface material; (2) waste inventory increasing above the amount previously estimated; (3) waste disposal costs increasing above the amount previously estimated; (4) facility modifications; (5) changes in authorized possession limits; (6) actual remediation costs that exceed the previous cost estimate; (7) onsite disposal; and (8) use of a settling pond. If the amount of the financial assurance instrument will be adjusted to match the DFP, this cannot be done until the updated DFP is approved by the NRC. If the financial assurance instrument is revised (amended) to change the amount of financial assurance obligated, then you will need to also submit a revised Certificate of Financial Assurance (CFA) with the new amount.

J Baxter

2

Your cooperation is appreciated.

Sincerely,

A handwritten signature in black ink, appearing to read "Dennis R. Lawyer", with a long, sweeping horizontal flourish extending to the right.

Dennis R. Lawyer, Health Physicist
Commercial, Industrial, R&D
and Academic Branch
Division of Nuclear Materials Safety
Region I

License No. 06-19183-01
Docket No. 03017101
Mail Control No. 594341

cc: William L. Galdenzi, Radiation Safety Officer

J Baxter

2

Your cooperation is appreciated.

Sincerely,

Dennis R. Lawyer, Health Physicist
Commercial, Industrial, R&D
and Academic Branch
Division of Nuclear Materials Safety
Region I

License No. 06-19183-01
Docket No. 03017101
Mail Control No. 599809

cc: William L. Galdenzi, Radiation Safety Officer

DOCUMENT NAME: G:\WBL Documents\WBL License Cover Letter\L06-19183-01.599809.docx

[LAT to enter ADAMS Accession No.]

SUNSI Review Complete: DLawyer

After declaring this document "An Official Agency Record" it will be released to the Public.

To receive a copy of this document, indicate in the box: "C" = Copy w/o attach/encl "E" = Copy w/ attach/encl "N" = No copy

OFFICE	RI:DNMS	N					
NAME	DLawyer						
DATE	6/14/2017						

OFFICIAL RECORD COPY